At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 82 enrolled
Drug / intervention
IRL757 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled, Phase I, First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating IRL757 and Placebo for Not Determined. Completed, enrolled 82 participants across 1 site.
Detailed Summary
This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNot Determined
CountriesSweden
CollaboratorsMichael J. Fox Foundation for Parkinson's Research
Timeline
Phase 1CompletedFinished
20252026
Enrollment StartMay 2024
First PostedJul 2024
Primary CompletionFeb 2025
TodayJul 2026
First PostedJul 9, 2024
Enrollment StartMay 16, 2024
Primary CompletionFeb 7, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.0 years ago
Interventions
IRL757drug
IRL757 capsule
Placebodrug
Placebo capsule